Cargando…

Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis

Background: Soluble CD163 (sCD163) is a scavenger receptor membrane protein expressed almost exclusively on Kupffer cells and other macrophages. It was found to be associated with the severity of liver cirrhosis. The aim of the present study was to determine whether the novel biomarker sCD163 predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yue, Huang, Chenkai, Nie, Yuan, Liu, Qi, Xiao, Nanxi, Liu, Linxiang, Zhu, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319469/
https://www.ncbi.nlm.nih.gov/pubmed/34336902
http://dx.doi.org/10.3389/fmed.2021.698502
_version_ 1783730453948137472
author Zhang, Yue
Huang, Chenkai
Nie, Yuan
Liu, Qi
Xiao, Nanxi
Liu, Linxiang
Zhu, Xuan
author_facet Zhang, Yue
Huang, Chenkai
Nie, Yuan
Liu, Qi
Xiao, Nanxi
Liu, Linxiang
Zhu, Xuan
author_sort Zhang, Yue
collection PubMed
description Background: Soluble CD163 (sCD163) is a scavenger receptor membrane protein expressed almost exclusively on Kupffer cells and other macrophages. It was found to be associated with the severity of liver cirrhosis. The aim of the present study was to determine whether the novel biomarker sCD163 predicts outcomes in patients with decompensated cirrhosis. Materials and Methods: A single-center, observational, prospective study with 345 decompensated cirrhosis patients was conducted in the Gastroenterology Department between January 2017 and December 2020. Their plasma samples were tested by enzyme-linked immunosorbent assay (ELISA) for sCD163 within 24 hours of admission. These patients were followed up at 28 days, 3 months and 6 months. The independent risk factors were identified with uni- and multivariate logistic regression analyses. We evaluated the predictive performance of the new scoring system (including sCD163) and the original scoring system. Results: The sCD163 level was significantly higher in non-surviving patients than in surviving patients. Positive associations were found between sCD163 levels and the Child-Turcotte-Pugh (CTP), Model for End-Stage Liver Disease (MELD) and albumin-bilirubin (ALBI) scores. Logistic regression confirmed that sCD163 was an independent risk factor for 28-day, 3-month, and 6-month mortality. The areas under the receiver operating characteristic curves (AUROCs) of the use of sCD163 for the prediction of 28-day, 3-month, and 6-month mortality were relatively higher (AUROCs: 0.856; 0.823 and 0.811, respectively). The AUROCs of the new scores obtained by adding sCD163 to the original scoring systems (CTP + sCD163, MELD + sCD163 and ALBI + sCD163) showed that the new scoring systems had better predictive performance than the original scoring systems at all time points (P < 0.001). Conclusion: sCD163 is a prognostic predictor of short-term and long-term outcomes in decompensated cirrhosis patients. Accordingly, the addition of sCD163 to the original clinical scoring systems improved their prognostic performance.
format Online
Article
Text
id pubmed-8319469
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83194692021-07-30 Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis Zhang, Yue Huang, Chenkai Nie, Yuan Liu, Qi Xiao, Nanxi Liu, Linxiang Zhu, Xuan Front Med (Lausanne) Medicine Background: Soluble CD163 (sCD163) is a scavenger receptor membrane protein expressed almost exclusively on Kupffer cells and other macrophages. It was found to be associated with the severity of liver cirrhosis. The aim of the present study was to determine whether the novel biomarker sCD163 predicts outcomes in patients with decompensated cirrhosis. Materials and Methods: A single-center, observational, prospective study with 345 decompensated cirrhosis patients was conducted in the Gastroenterology Department between January 2017 and December 2020. Their plasma samples were tested by enzyme-linked immunosorbent assay (ELISA) for sCD163 within 24 hours of admission. These patients were followed up at 28 days, 3 months and 6 months. The independent risk factors were identified with uni- and multivariate logistic regression analyses. We evaluated the predictive performance of the new scoring system (including sCD163) and the original scoring system. Results: The sCD163 level was significantly higher in non-surviving patients than in surviving patients. Positive associations were found between sCD163 levels and the Child-Turcotte-Pugh (CTP), Model for End-Stage Liver Disease (MELD) and albumin-bilirubin (ALBI) scores. Logistic regression confirmed that sCD163 was an independent risk factor for 28-day, 3-month, and 6-month mortality. The areas under the receiver operating characteristic curves (AUROCs) of the use of sCD163 for the prediction of 28-day, 3-month, and 6-month mortality were relatively higher (AUROCs: 0.856; 0.823 and 0.811, respectively). The AUROCs of the new scores obtained by adding sCD163 to the original scoring systems (CTP + sCD163, MELD + sCD163 and ALBI + sCD163) showed that the new scoring systems had better predictive performance than the original scoring systems at all time points (P < 0.001). Conclusion: sCD163 is a prognostic predictor of short-term and long-term outcomes in decompensated cirrhosis patients. Accordingly, the addition of sCD163 to the original clinical scoring systems improved their prognostic performance. Frontiers Media S.A. 2021-07-15 /pmc/articles/PMC8319469/ /pubmed/34336902 http://dx.doi.org/10.3389/fmed.2021.698502 Text en Copyright © 2021 Zhang, Huang, Nie, Liu, Xiao, Liu and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Zhang, Yue
Huang, Chenkai
Nie, Yuan
Liu, Qi
Xiao, Nanxi
Liu, Linxiang
Zhu, Xuan
Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis
title Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis
title_full Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis
title_fullStr Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis
title_full_unstemmed Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis
title_short Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis
title_sort soluble cd163 is a predictor of mortality in patients with decompensated cirrhosis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319469/
https://www.ncbi.nlm.nih.gov/pubmed/34336902
http://dx.doi.org/10.3389/fmed.2021.698502
work_keys_str_mv AT zhangyue solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis
AT huangchenkai solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis
AT nieyuan solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis
AT liuqi solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis
AT xiaonanxi solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis
AT liulinxiang solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis
AT zhuxuan solublecd163isapredictorofmortalityinpatientswithdecompensatedcirrhosis